PRQR

ProQR Therapeutics N.V.

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

ProQR Therapeutics N.V. (PRQR) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Momentum (C). The rating has held at C+ for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
B-
Factor Score 2.9 / 5.0
Growth
C+
Factor Score 2.6 / 5.0
Profitability
B
Factor Score 3.4 / 5.0
Momentum
C
Factor Score 2.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.0
EV / EBITDA -2.2
Rev Growth YoY 120.4%
Gross Margin N/M
Price Return 3M -26.9%
Price Return 12M -34.7%
Catalyst Signal 0.00
Market Cap $199.3M
TTM Revenue $18.4M
Price / Sales 10.8
ROE -57.4%

Historical Factor Score Progression

Held C+ for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B- (2.9) C+ (2.6) B (3.4) C (2.2) C+ (2.6) C+ (2.7)
2026-11-07 B- (3.0) C+ (2.7) B (3.4) C (2.3) C+ (2.7) C+ (2.8)
2026-10-31 B- (3.0) C+ (2.7) B (3.4) C (2.4) C+ (2.7) C+ (2.8)
2026-10-24 B- (3.0) C+ (2.6) B (3.4) C (2.2) C+ (2.6) C+ (2.8)
2026-10-17 B- (3.0) C+ (2.6) B (3.4) C- (2.1) C+ (2.6) C+ (2.8)
Page 1 of 3